How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,606 results for

Testicular Cancer

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Comparison of Tissue Stiffness Using Shear Wave Elastography in Men with Normal Testicular Tissue, Testicular Microlithiasis and Testicular Cancer (PubMed)

Comparison of Tissue Stiffness Using Shear Wave Elastography in Men with Normal Testicular Tissue, Testicular Microlithiasis and Testicular Cancer To compare elastography measurements in men with normal testicular tissue, testicular microlithiasis and testicular cancer.A total of 248 consecutive patients were included. All men provided written informed consent. Testicular stiffness was assessed using shear wave elastography (SWE). Three SWE velocity measurements were assessed in each testicle (...) . The patients were divided into three groups; men with normal testicular tissue (n=130), men with testicular microlithiasis (n=99) and men with testicular cancer (n=19).We found a higher mean velocity in the group of patients with testicular cancer (1.92 m/s (95% CI 1.82-2.03)) compared to both the group with normal tissue (0.76 m/s (95% CI: 0.75-0.78)) (p<0.001) and the group with testicular microlithiasis 0.79 m/s (95% CI: 0.77-0.81) (p<0.001).The presence of testicular microlithiasis increased stiffness

Full Text available with Trip Pro

2017 Ultrasound international open

4. Testicular cancer

Testicular cancer Testicular cancer - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Testicular cancer Last reviewed: February 2019 Last updated: January 2018 Summary Most commonly presents as a hard, painless nodule on one testis noticed by the patient or at a regular clinic examination. Elevated serum tumour markers can be used for disease diagnosis and aid in monitoring the treatment response. Ultrasound (...) extratesticular manifestation cryptorchidism gonadal dysgenesis family history of testicular cancer personal history of testicular cancer testicular atrophy white ethnicity HIV infection chemical carcinogens and low sperm count rural residence higher socioeconomic status inguinal hernia genetic abnormality of chromosome 12 Diagnostic investigations ultrasound (colour Doppler) of testis CT scan (abdomen and pelvis) serum beta-human chorionic gonadotrophin (beta-hCG) serum alpha-fetoprotein (AFP) serum lactate

2018 BMJ Best Practice

5. Testicular Cancer

Testicular Cancer Testicular Cancer | Uroweb › Testicular Cancer Testicular Cancer To access the pdfs & translations of individual guidelines, please as EAU member. Non-EAU members can view the web versions. To become an EAU member, click . M.P. Laguna (Chair), P. Albers, W. Albrecht, F. Algaba, C. Bokemeyer, J.L. Boormans, G. Cohn-Cedermark, K. Fizazi, H. Gremmels (Patient advocate), A. Horwich, D. Nichol, N. Nicolai, J. Oldenburg Guidelines Associates: J. Mayor de Castro, Ch. Fankhauser TABLE (...) OF CONTENTS REFERENCES 1. Albers, P., et al. Guidelines on Testicular Cancer: 2015 Update. Eur Urol, 2015. 68: 1054. 2. Guyatt, G.H., et al. What is “quality of evidence” and why is it important to clinicians? BMJ, 2008. 336: 995. 3. Guyatt, G.H., et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ, 2008. 336: 924. 4. Phillips B, et al. Oxford Centre for Evidence-based Medicine Levels of Evidence. Updated by Jeremy Howick March 2009. 1998. 5. Guyatt, G.H

2019 European Association of Urology

6. Diagnosis and Treatment of Early Stage Testicular Cancer

Diagnosis and Treatment of Early Stage Testicular Cancer Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline (2019) - American Urological Association advertisement Toggle navigation About Us About the AUA Membership AUA Governance Industry Relations Education AUAUniversity Education Products & Resources Normal Histology and Important Histo-anatomic Structures Urinary Bladder Prostate Kidney Renovascular Diseases Andrenal Gland Testis Paratesticular Tumors Penis (...) and Reimbursement Practice Managers' Network (PMN) Patient Safety and Quality of Care Accreditations and Reporting Patient Education Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline (2019) AUA Guideline Published 2019 [pdf] [pdf] Panel Members Andrew Stephenson, MD; Scott E. Eggener, MD; Eric B. Bass, MD, MPH; David M. Chelnick, BS; Siamak Daneshmand, MD; Darren Feldman, MD; Timothy Gilligan, MD; Jose A. Karam, MD; Bradley Leibovich, MD, FACS; Stanley L. Liauw, MD; Timothy A. Masterson

2019 American Urological Association

7. Sperm cryopreservation incidence in men with testicular cancer: towards a stabilization in testicular cancer incidence? Results from the CECOS network (PubMed)

Sperm cryopreservation incidence in men with testicular cancer: towards a stabilization in testicular cancer incidence? Results from the CECOS network Testicular cancer (TC) represents 1% of all new male cancer cases but remains the most frequent cancer in adolescents and young adults in industrialized countries. In this study, we assessed time trends in use of sperm cryopreservation by men with TC from 1990 to 2013 in France.We collected data from patients diagnosed with TC who underwent sperm

Full Text available with Trip Pro

2018 Basic and Clinical Andrology

8. Second cancers and causes of death in patients with testicular cancer in Sweden. (PubMed)

Second cancers and causes of death in patients with testicular cancer in Sweden. While treatment for testicular cancer (TC) has become standardized after the 1980s with an associated significant improvement in patient survival, this has been accompanied by an increased risk of second primary cancers (SPCs). Patients were identified from the Swedish Cancer Registry spanning the years from 1980 to 2015, including 8788 individuals with primary TC and their SPCs. Relative risks (RRs) for SPC were (...) calculated using the generalized Poisson regression model. SPCs were diagnosed in 9.4% of patients with TC and half of them were late onset cancers not common in the population in their 40s. Overall RR of SPCs (excluding second TC) was 1.30 (95%CI: 1.20-1.40), including high risks for seven solid cancers, non-Hodgkin lymphoma and leukemia. Second TC was the most common SPC and the RR of 17.19 (95%CI: 14.89-19.85) was the highest recorded. Cancers known to be fatal as first primary cancers were also fatal

Full Text available with Trip Pro

2019 PLoS ONE

9. ESMO Consensus Conference Guidelines on testicular germ cell cancer: diagnosis, treatment and follow-up

ESMO Consensus Conference Guidelines on testicular germ cell cancer: diagnosis, treatment and follow-up SPECIAL ARTICLE ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up F. Honecker 1,2 * , J. Aparicio 3 , D. Berney 4 , J. Beyer 5 , C. Bokemeyer 2 , R. Cathomas 6 , N. Clarke 7 , G. Cohn-Cedermark 8 , G. Daugaard 9 , K.-P. Dieckmann 10 , K. Fizazi 11 , S. Fossa ° 12 , J. R. Germa-Lluch 13 , P. Giannatempo 14 , J. A. Gietema 15 , S. Gillessen 16,17 , H (...) - meetingdiscussionsinwrittenform.Thismanuscriptpresentstheresultsoftheexpertpaneldiscussions,includingtheconsensus recommendationsandasummaryofevidencesupportingeachrecommendation.Allparticipantsapprovedthefinalmanuscript. Keywords: testicular germ cell cancer, consensus, diagnosis, treatment, quality of life, follow-up V C The Author(s) 2018. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. Annals of Oncology 29: 1658–1686, 2018 doi:10.1093/annonc/mdy217

2018 European Society for Medical Oncology

10. Successful onco-testicular sperm extraction from a testicular cancer patient with a single testis and azoospermia (PubMed)

Successful onco-testicular sperm extraction from a testicular cancer patient with a single testis and azoospermia Onco-testicular sperm extraction is used to preserve fertility in patients with bilateral testicular tumors and azoospermia. We report the case of a testicular tumor in the solitary testis of a patient who had previously undergone successful contralateral orchiectomy and whose sperm was preserved by onco-testicular sperm extraction. A 35-year-old patient presented with swelling (...) of his right scrotum that had lasted for 1 month. His medical history included a contralateral orchiectomy during childhood. Ultrasonography revealed a mosaic echoic area in his scrotum, suggesting a testicular tumor. The lesion was palpated within the normal testicular tissue along its edge and semen analysis showed azoospermia. Radical inguinal orchiectomy and onco-testicular sperm extraction were performed simultaneously. Motile spermatozoa were extracted from normal seminiferous tubules under

Full Text available with Trip Pro

2018 Clinical and experimental reproductive medicine

11. Onco-testicular sperm extraction (Onco-TESE) from a single testis with metachronous bilateral testicular cancer: a case report (PubMed)

Onco-testicular sperm extraction (Onco-TESE) from a single testis with metachronous bilateral testicular cancer: a case report Although oncologic testicular sperm extraction (onco-TESE) has been increasingly practiced, the evidence of onco-TESE performed in patients with testicular cancer is insufficient. Furthermore, in bilateral testicular cancer, accounting for 0.5%-1% of testicular cancers, onco-TESE is more challenging and has been insufficiently reported.Here we report the case of a 25 (...) testicular cancer.

Full Text available with Trip Pro

2018 Basic and Clinical Andrology

12. Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers. (PubMed)

Current controversies on the role of lymphadenectomy for testicular cancer for the journal: Urologic Oncology: Seminars and Original Investigations for the special seminars section on the role of lymphadenectomy for urologic cancers. The role of surgery in the locoregional management of many solid tumors has long been established. For testicular cancer, the incorporation of lymphadenectomy has played an important part in generating long-term survival outcomes in excess of 90% for germ cell

2019 Urologic oncology

13. Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study. (PubMed)

Family history of cancer and risk of paediatric and young adult's testicular cancer: A Norwegian cohort study. The aim of this study was to examine the association of a family history of cancer with the risk of testicular cancer in young adults.This is a prospective cohort study including 1,974,287 males born 1951-2015, of whom 2686 were diagnosed with TC before the age of 30.A history of TC in male relatives was significantly associated with a diagnosis of TC among children and young adults (...) ). The risk of TC was also increased when fathers (11.1-fold), paternal (4.9-fold) and maternal uncles and aunts (4.6-fold) were diagnosed with malignant neuroepithelial-tumours.We found an increased risk of TC among children and young adults with a family history of TC, carcinoma, mesothelioma, sarcoma, malignant melanoma and malignant neuroepithelial tumours. Hereditary cancer syndromes might underlie some of the associations reported in this study.

2019 British Journal of Cancer

14. Ultrasound Evaluation of Testicular Volume in Patients with Testicular Microlithiasis (PubMed)

Ultrasound Evaluation of Testicular Volume in Patients with Testicular Microlithiasis Ultrasonography is a useful tool to measure testicular volume. According to the European Society of Urogenital Radiology, the combination of testicular atrophy and testicular microlithiasis (TML) is a risk factor for testicular cancer. Testicular atrophy is defined as a volume of less than 12 ml. The aim of this study was to compare testicular volume in patients with TML to patients with normal testicular (...) tissue.From 2013 to 2015 we included a total of 91 adult patients with TML, and 91 adult patients with normal testicular tissue as a control group. All patients underwent scrotal B-mode ultrasound investigation including measurement of width, length and height in both testicles. Testicular volume was calculated using the formula π/6×length×height×width.The median age for patients with TML was 48 years (range: 19-94 years), and 48 years (range: 20-75 years) in patients with normal tissue. No statistically

Full Text available with Trip Pro

2018 Ultrasound international open

15. Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary

Non-risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary Cancer-specific survival for men with clinical stage I testicular cancer (CSITC) is uniformly excellent. Non-risk-adapted active surveillance (NRAS) is a management strategy for CSITC to minimize overtreatment and avoid possible long-term side effects of adjuvant therapy.To review the evidence regarding oncologic outcomes for men with CSITC undergoing NRAS and discuss ongoing controversies in the management (...) with clinically localized (stage I) testicular cancer have an excellent prognosis, regardless of management. Non-risk-adapted active surveillance is an attractive management option where only patients destined to relapse will receive any treatment following orchiectomy. However, individual patient preferences should be discussed in selecting a management strategy.Copyright © 2018 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2018 EvidenceUpdates

16. Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. (PubMed)

Testicular Tumour Size and Rete Testis Invasion as Prognostic Factors for the Risk of Relapse of Clinical Stage I Seminoma Testis Patients Under Surveillance: a Systematic Review by the Testicular Cancer Guidelines Panel. Patients with clinical stage I (CS I) seminoma testis with large primary tumours and/or rete testis invasion (RTI) might have an increased risk of relapse. In recent years, these risk factors have frequently been employed to decide on adjuvant treatment.To systematically (...) . Furthermore, the evidence on the prognostic value of size and RTI has significant limitations, so prudency is warranted on their routine use in clinical practice.Primary testicular tumour size and rete testis invasion are considered to be important prognostic factors for the risk of relapse in patients with clinical stage I seminoma testis. We systematically reviewed all the literature on the prognostic value of these two postulated risk factors. The outcome is that the prognostic power of these factors

2017 European Urology

17. Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. (PubMed)

Reporting and Staging of Testicular Germ Cell Tumors: The International Society of Urological Pathology (ISUP) Testicular Cancer Consultation Conference Recommendations. The International Society of Urological Pathology held a conference devoted to issues in testicular and penile pathology in Boston in March 2015, which included a presentation and discussion led by the testis microscopic features working group. This conference focused on controversies related to staging and reporting (...) of testicular tumors and was preceded by an online survey of the International Society of Urological Pathology members. The survey results were used to initiate discussions, but decisions were made by expert consensus rather than voting. A number of recommendations emerged from the conference, including that lymphovascular invasion (LVI) should always be reported and no distinction need be made between lymphatic or blood invasion. If LVI is equivocal, then it should be regarded as negative to avoid

2017 American Journal of Surgical Pathology

18. An Uncommon Presentation of a Metachronous Testicular Primary Nonseminoma and Seminoma Separated by Two Decades and a Testicular Cancer Literature Review (PubMed)

An Uncommon Presentation of a Metachronous Testicular Primary Nonseminoma and Seminoma Separated by Two Decades and a Testicular Cancer Literature Review Testicular cancer is the most common malignancy in men aged 15-40 years [Bols et al.: Philadelphia, Wolters Kluwer, Lippincott Williams & Wilkins, 2011]. Its incidence comprises 0.8% of all male cancers worldwide, with a mortality rate of 0.1%. The incidence has nearly doubled from 1975 to 2007 leading to the concern of environmental causes (...) [Thomas: Am J Epidemiol 2013; 178: 1240-1245]. Testicular cancer presents as a painless testicular mass without transillumination. Testicular cancer is subcategorized under germ cell testicular cancer or sex cord-stromal tumors. Of the germ cell tumors, approximately 90% originate in the testis, with the other 10% being extragonadal [Bols et al.: Philadelphia, Wolters Kluwer, Lippincott Williams & Wilkins, 2011]. Typically, if a patient presents with a testicular mass and is 50 years old or older

Full Text available with Trip Pro

2017 Case reports in oncology

19. Testicular Cancer Treatment (PDQ®): Patient Version

Testicular Cancer Treatment (PDQ®): Patient Version Testicular Cancer Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002 (...) -. Search term Testicular Cancer Treatment (PDQ®) Patient Version PDQ Adult Treatment Editorial Board . Published online: October 26, 2018. This PDQ cancer information summary has current information about the treatment of testicular cancer. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards

2018 PDQ - NCI's Comprehensive Cancer Database

20. Chemotherapy in a Patient With G6PD Deficiency and Advanced Testicular Cancer (PubMed)

Chemotherapy in a Patient With G6PD Deficiency and Advanced Testicular Cancer 30241168 2019 03 04 2378-9506 4 2018 Sep Journal of global oncology J Glob Oncol Chemotherapy in a Patient With G6PD Deficiency and Advanced Testicular Cancer. 1-4 10.1200/JGO.17.00034 Uema Deise D Deise Uema, Cheng Tzu Yen, Diogo Assed Bastos, and Gilberto de Castro Jr, Hospital Sírio-Libanês; Denyei Nakazato, Santa Paula Hospital; and Eduardo Perrone, Federal University of São Paulo, São Paulo, Brazil. Nakazato

Full Text available with Trip Pro

2017 Journal of global oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>